Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

CeriXMedical Esthetics ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 0.7% 0.7%   Bankruptcy risk   2.1% 3.1% 1.1% 0.9% 4.9% 9.9% 10.1% 9.9%   Credit score (0-100)   69 58 83 89 44 24 24 25   Credit rating   BBB BBB A A BBB BB BB BB   Credit limit (kDKK)   0.2 0.0 231.9 665.9 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   5,295 8,203 6,741 6,227 3,064 594 0.0 0.0   EBITDA   1,525 2,178 1,957 2,852 -921 -4,365 0.0 0.0   EBIT   978 1,530 1,316 2,665 -1,083 -4,612 0.0 0.0   Pre-tax profit (PTP)   1,017.6 1,769.7 1,785.6 2,922.3 -743.9 -4,686.2 0.0 0.0   Net earnings   789.3 1,375.8 1,387.6 2,284.4 -597.0 -3,693.6 0.0 0.0   Pre-tax profit without non-rec. items   1,018 1,770 1,786 2,922 -744 -4,686 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   908 989 776 1,249 1,088 861 0.0 0.0   Shareholders equity total   1,166 2,542 3,929 6,214 5,455 1,762 1,712 1,712   Interest-bearing liabilities   442 3,483 0.0 107 750 5,071 0.0 0.0   Balance sheet total (assets)   6,091 11,762 8,754 10,754 10,308 10,025 1,712 1,712   Net Debt   -1,073 3,314 -1,782 -15.5 317 4,364 -1,712 -1,712     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   5,295 8,203 6,741 6,227 3,064 594 0.0 0.0   Gross profit growth   100.1% 54.9% -17.8% -7.6% -50.8% -80.6% -100.0% 0.0%   Employees   5 11 10 6 8 9 0 0   Employee growth %   66.7% 120.0% -9.1% -40.0% 33.3% 12.5% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   6,091 11,762 8,754 10,754 10,308 10,025 1,712 1,712   Balance sheet change%   83.4% 93.1% -25.6% 22.8% -4.1% -2.7% -82.9% 0.0%   Added value   1,525.5 2,178.4 1,957.2 2,852.4 -895.8 -4,364.9 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -548 -567 -854 286 -323 -474 -861 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 -1.0 -2.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   18.5% 18.7% 19.5% 42.8% -35.3% -776.1% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   21.6% 20.1% 17.7% 30.1% -6.8% -42.2% 0.0% 0.0%   ROI %   72.0% 45.1% 33.9% 50.8% -10.6% -64.9% 0.0% 0.0%   ROE %   102.3% 74.2% 42.9% 45.0% -10.2% -102.4% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   19.1% 21.6% 45.0% 58.0% 53.3% 17.8% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -70.4% 152.1% -91.1% -0.5% -34.4% -100.0% 0.0% 0.0%   Gearing %   37.9% 137.0% 0.0% 1.7% 13.7% 287.9% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.2% 1.3% 1.6% 25.5% 6.5% 13.6% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   1.0 1.1 1.8 2.4 1.9 1.1 0.0 0.0   Current Ratio   1.1 1.2 1.8 2.6 2.1 1.1 0.0 0.0   Cash and cash equivalent   1,515.2 169.4 1,782.3 122.1 432.5 707.1 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   320.2 1,711.9 3,629.3 5,780.2 4,801.3 1,159.5 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   305 198 196 475 -112 -485 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   305 198 196 475 -115 -485 0 0   EBIT / employee   196 139 132 444 -135 -512 0 0   Net earnings / employee   158 125 139 381 -75 -410 0 0